Loading...
Docoh

024 Pharma (EEIG)

Document and Entity Information

Document and Entity Information - shares6 Months Ended
Jun. 30, 2016Oct. 20, 2016
Document And Entity Information
Entity Registrant Name024 Pharma, Inc.
Entity Central Index Key1307969
Document Type10-Q
Document Period End DateJun. 30,
2016
Amendment Flagfalse
Current Fiscal Year End Date--12-31
Is Entity a Well-known Seasoned Issuer?No
Is Entity a Voluntary Filer?Yes
Is Entity's Reporting Status Current?No
Entity Filer CategorySmaller Reporting Company
Entity Common Stock, Shares Outstanding336,354,321
Document Fiscal Period FocusQ2
Document Fiscal Year Focus2016

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited)Jun. 30, 2016USD ($)
Current
Cash $ 17,463
Harmonized sales tax recoverable32,962
Due from related companies5,432
Total current assets55,857
Equipment3,575
Total assets59,432
Current
Accounts payable and accrued charges9,890
Accrued management salaries5,750
Income taxes payable8,937
Advances from shareholder3,655
Total current liabilities28,233
SHAREHOLDERS' EQUITY
Share Capital1
Retained Earnings31,199
Total shareholders' equity31,200
Total liabilities and shareholders' equity $ 59,432

Condensed Statement of Earnings

Condensed Statement of Earnings (Unaudited)6 Months Ended
Jun. 30, 2016USD ($)
Income Statement [Abstract]
Sales $ 343,610
Cost of Sales218,035
Gross Profit125,575
Expenses
Shipping costs40,305
Selling expenses11,334
Advertising and promotion16,009
Management bonus5,750
Salaries and benefits3,561
Occupancy costs3,471
Subcontracts2,524
Repairs and maintenance624
Travel580
Office and general550
Professional fees506
Vehicle expense66
Telephone and telecommunications64
Interest and bank charges29
Amortization579
Total operating expenses85,950
Earnings Before Income Taxes39,625
Provision for income taxes8,937
Net Earnings $ 30,687

Condensed Statement of Retained

Condensed Statement of Retained Earnings6 Months Ended
Jun. 30, 2016USD ($)
Beginning balance $ 512
Net earnings30,687
Ending balance $ 31,200

1. Background

1. Background6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. BackgroundB Green Innovations,
Inc., a Matawan, New Jersey-based corporation, (OTC Pink® marketplace: BGNN), formerly iVoice Technology, Inc., (“B
Green Innovations” or the “Company”) was incorporated under the laws of New Jersey on November 10, 2004 as a
wholly owned subsidiary of iVoice, Inc. (“iVoice”). In May 2008, the Company formed B Green Innovations,
Inc. (“B Green”), a wholly-owned subsidiary to commercialize its “green” technology platforms. On November 17,
2009, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), B Green Innovations, Inc., a wholly owned
subsidiary of iVoice Technology, Inc., merged into iVoice Technology, Inc. On July 28, 2009,
the Board of Directors and shareholders through written consent representing a majority of the total voting Class A and Class
B Common stock voted to change the name of the Company to B Green Innovations, Inc. On November 20, 2009, the Company
filed an Amendment to the Certificate of Incorporation with the State of New Jersey to officially change the name of the Company. On October 8,
2016, the Registrant’s Board of Directors, acting pursuant to its Amended Articles of Incorporation, unanimously approved
to change the name of the Registrant from B Green Innovations, Inc. to 024 Pharma, Inc. by amending Article One of the Registrant’s
Articles of Incorporation. The purpose of the name change is to more fully encapsulate the Registrant’s current operations
and business direction. The New Jersey Secretary of State, effective October 12, 2016, processed the name change and the Registrant
has filed for a symbol change with the Financial Industry Regulatory Authority (“FINRA”). The Company will also obtain
a new CUSIP number in connection with the name change.

2. Business Operations

2. Business Operations6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2. Business Operations024 Pharma, Inc.
provides the best nutrition in every area that matters. From vitamin and mineral supplements, stress release, joint and heart
health, and weight-loss products, skin care, healthy hair and anti-aging. 024 Pharma, Inc.
gives you what you need to create healthier lives for you and your family. 024 Pharma, Inc.
is known in the international market for its unique global shareholders system. Company promotes the concept of "People-oriented,
Just and Equitable" which received high appraisal from the majority of the personage from the industry. Everyone can join
and become a shareholder. Everyone can share the return on 024's Pharma, Inc's investment. 024 Pharma, Inc. is destined to become
the most influential and competitive shareholders group. 024 Pharma’s
premium quality products do more than improve people’s health—they transform their lives. Sourced, manufactured and
tested against the most rigorous quality standards, our unique product portfolio delivers more than over 220 personalized solutions
to optimize your health. Company’s
staff science team formulates products with a relentless commitment to ingredient purity and potency. That’s why customers
trust theirr products to deliver proven, repeatable results. 024 Pharma make
and package products in their own facility, under conditions and guidelines that meet the most stringent global regulations. Outfitted with
state-of-the-art instrumentation and combining the skills of accomplished scientists, researchers and medical professionals, our
research lab creates a unique environment in which to pursue scientific discovery and advancement, and it is the hub of our product
development and testing.

3. Going Concern

3. Going Concern6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
3. Going ConcernThe accompanying
condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States
of America, which contemplates continuation of the Company as a going concern. Management plans
to increase the development, manufacture, and distribution of products to generate a positive cash flow.

4. Summary of Significant Accou

4. Summary of Significant Accounting Policies6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]
4. Summary of Significant Accounting Policiesa) Basis
of Presentation The accompanying
condensed unaudited interim financial statements included herein have been prepared, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission ("SEC"). The condensed financial statements and notes are presented
as permitted on Form 10-Q and do not contain information included in the Company's annual statements and notes. Certain information
and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company
believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed
financial statements be read in conjunction with the March 31, 2015 financial statements and the accompanying notes thereto. While
management believes the procedures followed in preparing these condensed financial statements are reasonable, the accuracy of
the amounts are in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company
later in the year. These results are not necessarily indicative of the results to be expected for the full year. These condensed
unaudited financial statements reflect all adjustments, including normal recurring adjustments, which, in the opinion of management,
are necessary to present fairly the operations and cash flows for the periods presented. b) Use
of Estimates The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates. c) Revenue
Recognition In
addition to cash flow generated from sale of natural supplements such as:
· Diabetes
· Lung
cleanse
· Seal
oil
· Prostate
· Stress
less Company intends
to produce the “health phone” that will significantly increase demand in their product and enlarge the product purchase.
Clients will be able to purchase products through this smartphone and it contains application that measure heartbeat, calories,
fat, excises schedule etc. The most important thing is that clients will have this option to talk to health specialists. d) Product
Warranties The Company estimates
its warranty costs based on historical warranty claims experience in estimating potential warranty claims. Management has determined
that warranty costs are immaterial and has not included an accrual for potential warranty claims. Presently, costs related to
warranty coverage are expensed as incurred. Warranty claims are reviewed quarterly to verify that warranty liabilities properly
reflect any remaining obligation based on the anticipated expenditures over the balance of the obligation period. e) Research
and Development Costs Research and
development costs are charged to expense when incurred. The Company has not incurred any research and development costs for the
six months ended June 30, 2016. f) Advertising
Costs Advertising costs
are expensed as incurred and are included in selling expenses. The Company has incurred advertising costs for the six months ended
June 30, 2016 and it counts $16,008.72 USD. g) Cash
and Cash Equivalents The Company considers
all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. There were no
cash equivalents at June 30, 2016 and March 31, 2015. The Company maintains cash balances at financial institutions that are insured
by the Federal Deposit Insurance Corporation (“FDIC”) up to federally insured limits. At times balances may exceed
FDIC insured limits. The Company has not experienced any losses in such accounts. h) Concentration
of Credit Risk Financial instruments
that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable and cash.
As of June 30, 2016 the Company believes it has no significant risk related to its concentration within its accounts receivable. j) Accounts
Receivable Accounts receivable
are non-interest bearing obligations due under normal trade terms. Senior management reviews accounts receivable on a monthly
basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are
used in evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined
to be uncollectible, along with a general reserve, in its overall allowance for doubtful accounts. After all attempts to collect
a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company
believes its allowance for doubtful accounts as of June 30, 2016 and March 31, 2015 is adequate. j) Property
and Equipment Property and
equipment is stated at cost. Depreciation is computed using the straight-line method based upon the estimated useful lives of
the assets, generally five to seven years. Maintenance and repairs are charged to expense as incurred. k) Intangible
Assets Registration
and maintenance costs associated with the filing and registration of patents are prepaid and amortized over the remaining life
of the patent, not to exceed 20 years. Costs associated with such patents are not approved or abandoned. l) Income
Taxes The Company accounts
for income taxes using the asset and liability method described in FASB ASC 740. Deferred tax assets arise from a variety of sources,
the most significant being: a) tax losses that can be carried forward to be utilized against profits in future years; b) expenses
recognized in the books but disallowed in the tax return until the associated cash flow occurs; and c) valuation changes of assets
which need to be tax effected for book purposes but are deductible only when the valuation change is realized. Deferred tax
assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities
and are measured using enacted tax rates and laws that are expected to be in effect when such differences are expected to reverse. The
measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefit, which is not more likely
than not to be realized. In assessing the need for a valuation allowance, future taxable income is estimated, considering the
realization of tax loss carryforwards. Valuation allowances related to deferred tax assets can also be affected by changes to
tax laws, changes to statutory tax rates and future taxable income levels. In the event it was determined, that the Company would
not be able to realize all or a portion of our deferred tax assets in the future, we would reduce such amounts through a charge
to income in the period in which that determination is made. Conversely, if we were to determine that we would be able to realize
our deferred tax assets in the future in excess of the net carrying amounts, we would decrease the recorded valuation allowance
through an increase to income in the period in which that determination is made. In its evaluation of a valuation allowance, the
Company takes into account existing contracts and backlog, and the probability that options under these contract awards will be
exercised as well as sales of existing products. The Company prepares profit projections based on the revenue and expenses forecast
to determine that such revenues will produce sufficient taxable income to realize the deferred tax assets. The Company adopted
FASB ASC 740-10-50, Accounting for Uncertainty in Income Taxes. ASC 740-10-50 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
ASC 740-10 requires that the Company determine whether the benefits of its tax positions are more-likely-than-not of being sustained
upon audit based on the technical merits of the tax position. The Company recognizes the impact of an uncertain income tax position
taken on its income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing
authority. Despite the Company’s
belief that its tax return positions are consistent with applicable tax laws, one or more positions may be challenged by taxing
authorities. Settlement of any challenge can result in no change, a complete disallowance, or some partial adjustment reached
through negotiations or litigation. Interest and
penalties related to income tax matters, if applicable, will be recognized as income tax expense. During the three months ended
June 30, 2016 and 2015, the Company did not incur any expense related to interest or penalties for income tax matters, and no
such amounts were accrued as of June 30, 2016 and March 31, 2015. m) Fair
Value of Financial Instruments The carrying
amounts reported in the balance sheets as of June 30, 2016 and March 31, 2015 for cash and cash equivalents, marketable securities,
accounts receivable, inventories, prepaid expenses and other current assets, accounts payable and accrued expenses other current
liabilities approximate the fair value because of the immediate or short-term maturity of these financial instruments. The
fair value of the debt approximates its carrying value at the stated discount rate of the debt to reflect recent market conditions. n) Long-Lived
Assets The Company assesses
the recoverability of the carrying value of its long-lived assets whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of
the carrying amount of an asset to future, undiscounted cash flows expected to be generated by an asset. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets
exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less costs to sell. No impairment losses were recognized for the six months ended June 30, 2016 and 2015. o) Recent
Accounting Pronouncements There were various
other updates recently issued, most of which represented technical corrections to the accounting literature or application to
specific industries and are not expected to a have a material impact on the Company's financial position, results of operations
or cash flows.

7. Promissory Notes Payable

7. Promissory Notes Payable6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]
7. Promissory Notes PayableOn January 7,
2013, the Company executed a demand promissory note, with a value of $110,000, with an unrelated party to convert unpaid legal
fees to a promissory note. The note will bear interest at the rate of prime plus 1.0% per annum, with a default interest rate
of prime plus 2%, shall accrue interest monthly on the unpaid balance and shall be paid annually. Additional amounts may be advanced
by the holder and added to the principal of the note and accrue interest from the date of the advance. At various time during
2013 and 2014, the Company was notified that the unpaid principal and accrued interest on this note was assigned to other unrelated
parties and concurrent with the assignments, the Company consented to add conversion rights to the new owner. Under the terms
of the Securities and Settlement Agreements, the new owners can convert amounts due into shares of Class A Common Stock at a conversion
price of $.00005 (subsequently changed to $.50 per the reverse stock split) per shares and the ownership cannot exceed 9.99% at
any time. As of December 31, 2015, the holder of the note has fully liquidated the principal balance and accrued interest on this
note through the assignments of the note to other unrelated parties. On May 15, 2013
the Company executed a demand convertible promissory note, with a value of $110,788, with an unrelated party to convert unpaid
legal fees into various promissory notes. The notes will bear interest at the rate of prime plus 1.0% per annum, with a default
interest rate of prime plus 2%, shall accrue interest monthly on the unpaid balance and shall be paid annually. Additional amounts
may be advanced by the holder and added to the principal of the note and accrue interest from the date of the advance. Under the
terms of these promissory notes, at the option of the note holder, prepayment of principal and interest can be converted into
either (i) one share of Class B Common Stock of B Green Innovations, Inc., par value $.01, for each dollar owed, (ii) the number
of shares of Class A Common Stock of B Green Innovations, Inc. calculated by dividing (x) the sum of the principal and interest
that the note holder has requested to have prepaid by (y) eighty percent (80%) of the lowest issue price of Class A Common Stock
since the first advance of funds under this Note, or (iii) payment of the principal of this Note, before any repayment of interest.
The note holder is limited from beneficially owning more than 4.99% of the issued and outstanding shares of the Company’s
Class A Common Stock. The Board of Directors of the Company maintains control over the issuance of shares and may decline the
request for conversion of the repayment into shares of the Company. As of March 31, 2016, the holder has assigned an aggregate
of $64,941 of this note to other unrelated parties. As of March 31, 2016, the principal balance on this note was $45,846 and accrued
interest is $12,064. On August 14,
2013, the Company executed a demand convertible promissory note, with a value of $6,000, with unrelated party to secure additional
funding for the Company’s financing. The note will bear interest at the rate of prime plus 1.0% per annum, with a default
interest rate of prime plus 2%, shall accrue interest monthly on the unpaid balance and shall be paid annually. Additional amounts,
with an aggregate of $50,509 was advanced by the holder and added to the principal of the note and shall accrue interest from
the date of the advance. Under the terms of the promissory note, at the option of the note holder, prepayment of principal and
interest can be converted into either (i) one share of Class B Common Stock of B Green Innovations, Inc., par value $.01, for
each dollar owed, (ii) the number of shares of Class A Common Stock of B Green Innovations, Inc. calculated by dividing (x) the
sum of the principal and interest that the note holder has requested to have prepaid by (y) eighty percent (80%) of the lowest
issue price of Class A Common Stock since the first advance of funds under this Note, or (iii) payment of the principal of this
Note, before any repayment of interest. The note holder is limited from beneficially owning more than 4.99% of the issued and
outstanding shares of the Company’s Class A Common Stock. The Board of Directors of the Company maintains control over the
issuance of shares and may decline the request for conversion of the repayment into shares of the Company. As of March 31, 2016,
the principal balance on the note was $56,509 and accrued interest is $5,882. On October 1,
2013 the Company executed a demand convertible promissory note, with a value of $90,000, with an unrelated party to convert unpaid
legal fees into various promissory notes. The notes will bear interest at the rate of prime plus 1.0% per annum, with a default
interest rate of prime plus 2%, shall accrue interest monthly on the unpaid balance and shall be paid annually. Additional amounts
may be advanced by the holder and added to the principal of the note and accrue interest from the date of the advance. Under the
terms of these promissory notes, at the option of the note holder, prepayment of principal and interest can be converted into
either (i) one share of Class B Common Stock of B Green Innovations, Inc., par value $.01, for each dollar owed, (ii) the number
of shares of Class A Common Stock of B Green Innovations, Inc. calculated by dividing (x) the sum of the principal and interest
that the note holder has requested to have prepaid by (y) eighty percent (80%) of the lowest issue price of Class A Common Stock
since the first advance of funds under this Note, or (iii) payment of the principal of this Note, before any repayment of interest.
The note holder is limited from beneficially owning more than 4.99% of the issued and outstanding shares of the Company’s
Class A Common Stock. The Board of Directors of the Company maintains control over the issuance of shares and may decline the
request for conversion of the repayment into shares of the Company. As of March 31, 2016, the principal balance on this note was
$90,000 and accrued interest is $10,535. At various times
in 2013 and 2014, the Company consented to the assignments of the January 7, 2013 and the May 15, 2013 demand promissory notes,
with an aggregate value of $118,000, to other unrelated parties. Pursuant to the terms of the various agreements, the new owners
can convert amounts due into shares of Class A Common Stock at a conversion price of $.00005 (subsequently changed to $.50 per
the reverse stock split) per shares and the ownership cannot exceed 9.99% at any time. During 2013 and 2014, the new owners converted
$108,584 of this debt into approximately 10,136,371 (1,363,708,226 pre-reverse split plus 10,000,000 post split) shares of Class
A Common Stock. As of March 31, 2016, the new owners still have an unpaid balance of $27,360, representing principal and accrued
interest, of these notes. On April 1, 2014,
the Company executed an Original Issue Discount Convertible Promissory Note with an unrelated party to secure additional funding
for the Company’s financing. The face amount of the note is $37,500 and the purchase price was $25,000. The debt discount
of $12,500 was amortized monthly over the original term of the note. The note was due on March 28, 2015 and shall accrue late
fees of 22% per annum on all overdue unpaid principal. After the maturity date, the holder of the note can convert amounts due
for unpaid principal and accrued interest into shares of Class A Common Stock at a conversion price of $.00005 (subsequently changed
to $.50 per the reverse stock split) per share and their ownership cannot exceed 4.99% at any time. As of March 31, 2016, the
principal balance on the note was $37,500 and accrued interest was $8,340. On January 15,
2015, the Company issued a 8% Convertible Redeemable Note to LG Capital Funding. Amounts due under this note are due on or before
January 13, 2016. LG Capital Funding has the right to convert a portion or the entire outstanding principal into the Company's
Class A Common Stock at a Conversion Price equal to sixty percent (60%) of the lowest closing bid price of the Common Stock during
the twenty (20) trading days immediately preceding the Conversion Date. LG Capital Funding may not convert the note into shares
of Class A Common Stock if such conversion would result in LG Capital Funding beneficially owning in excess of 9.9% of the then
issued and outstanding shares of Class A Common Stock. During the three months ended March 31, 2016, the note holder converted
$7,116 of debt and accrued interest into 35,420,651 shares of Class A Common Stock. As of March 31, 2016, the outstanding balance
on this note was $72,200 and accrued interest was $9,587. In accordance
with ASC 815, "Derivatives and Hedging", the Company determined that the conversion feature of the LG Capital Funding
note met the criteria of an embedded derivative, and therefore the conversion feature of this debenture needed to be bifurcated
and accounted for as a derivative. The fair value of the embedded conversion was estimated at the date of issuance using the Black-Scholes
model with the following assumptions: risk free interest rate: 5.00%; expected dividend yield: 0%: expected life: 1 years; and
volatility: 332.49%. The accounting guidance instructs that the conversion options are a derivative liability. As such, on the
issue date, the Company recorded the conversion options as a liability of $128,588, recorded a debt discount of $78,750, and charged
Other Expense - Loss on Valuation of Derivative for $49,838. For the three months ended March 31, 2016, the Company recorded a
cumulative Loss on Valuation of Derivative in the amount of $43,544 on the fluctuation in the current market prices. On March 16,
2015, the Company consented to the assignments of a portion of the May 15, 2013 demand promissory notes (see above), with an aggregate
value of $55,394, to Tangiers Investment Group. Pursuant to the terms of the agreement, the new owners can convert amounts due
into shares of Class A Common Stock at a Conversion Price equal to sixty percent (60%) of the lowest trading price of the Common
Stock during the twenty (20) trading days immediately preceding the Conversion Date and the ownership cannot exceed 9.99% at any
time. During 2015, the new owners converted an aggregate of $55,394 of this debt into 55,582,636 shares of Class A Common Stock.
As of December 31, 2015, the new owners have fully liquidated the principal balance of this agreement. On March 19,
2015, the Company issued a 10% Convertible Promissory Note to Tangiers Investment Group. Amounts due under this note are due on
or before March 18, 2017. Tangiers Investment Group has the right to convert a portion or the entire outstanding principal into
the Company's Class A Common Stock at a Conversion Price equal to sixty percent (60%) of the lowest trading price of the Common
Stock during the twenty (20) trading days immediately preceding the Conversion Date. Tangiers Investment Group may not convert
the note into shares of Class A Common Stock if such conversion would result in the owners beneficially owning in excess of 9.99%
of the then issued and outstanding shares of Class A Common Stock. During the three months ended March 31, 2016, the note holder
converted $2,390 of debt into 19,916,667 shares of Class A Common Stock. As of March 31, 2016, the outstanding balance on this
note was $52,610 and accrued interest was $5,696. In accordance
with ASC 815, "Derivatives and Hedging", the Company determined that the conversion feature of the Tangiers Investment
Group notes met the criteria of an embedded derivative, and therefore the conversion feature of these debentures needed to be
bifurcated and accounted for as a derivative. The fair value of the embedded conversion was estimated at the date of issuance
using the Black-Scholes model with the following assumptions: risk free interest rate: 5.00%; expected dividend yield: 0%: expected
life: 2 years; and volatility: 308.61%. The accounting guidance instructs that the conversion options are a derivative liability.
As such, on the issue date, the Company recorded the aggregate conversion options as a liability of $234,143, recorded a debt
discount of $110,394, and charged Other Expense - Loss on Valuation of Derivative for $123,749. For the three months ended March
31, 2016, the Company recorded a Loss on Valuation of Derivative in the amount of $28,507 on the fluctuation in the current market
prices. On December 15,
2015, the Company issued a 10% Convertible Note to JSJ Investments Inc. Amounts due under this note are due on or before December
15, 2016. JSJ Investments Inc. has the right to convert a portion or the entire outstanding principal into the Company's Class
A Common Stock at a Conversion Price equal to 46% discount to the lowest trading price during the twenty (20) trading days to
the date of Conversion. JSJ Investments Inc. may not convert the note into shares of Class A Common Stock if such conversion would
result in the owners beneficially owning in excess of 4.99% of the then issued and outstanding shares of Class A Common Stock.
As of March 31, 2016, the outstanding balance on this note was $12,500 and accrued interest was $366. In accordance
with ASC 815, "Derivatives and Hedging", the Company determined that the conversion feature of the JSJ Investments Inc.
note met the criteria of an embedded derivative, and therefore the conversion feature of this debenture needed to be bifurcated
and accounted for as a derivative. The fair value of the embedded conversion was estimated at the date of issuance using the Black-Scholes
model with the following assumptions: risk free interest rate: 5.00%; expected dividend yield: 0%: expected life: 1 years; and
volatility: 197.44%. The accounting guidance instructs that the conversion options are a derivative liability. As such, on the
issue date, the Company recorded the conversion options as a liability of $26,464, recorded a debt discount of $12,500, and charged
Other Expense - Loss on Valuation of Derivative for $13,964. For the three months ended March 31, 2015, the Company recorded an
additional Loss on Valuation of Derivative in the amount of $7,874 on the fluctuation in the current market prices.

8. Related Party Transactions

8. Related Party Transactions6 Months Ended
Jun. 30, 2016
Related Party Transactions [Abstract]
8. Related Party TransactionsOn
May 8, 2007, the Company executed a Security Agreement providing Jerome Mahoney, President and Chief Executive Officer of the
Company, with a security interest in all of the assets of the Company to secure the promissory note dated August 5, 2005 and all
future advances including, but not limited to, additional cash advances: deferred compensation, deferred expense reimbursement,
deferred commissions and income tax reimbursement for the recognition of income upon the sale of common stock for the purpose
of the holder advancing additional funds to the Company. This security interest expired in 2012, as the UCC Financing Amendment
was never filed to continue the security interest of the creditor for the additional period provided by applicable law. The Company entered
into a five-year employment agreement with Jerome Mahoney to serve as Non-Executive Chairman of the Board of Directors, effective
August 1, 2004. On March 9, 2009, the term of the employment agreement between the Company and Mr. Mahoney, the Company’s
CEO, was extended to July 31, 2016. The Company will compensate Mr. Mahoney with a base salary of $85,000 for the first
year with annual increases based on the Consumer Price Index. Mr. Mahoney had a consulting agreement with the Company’s
former subsidiary B Green Innovations for annual compensation of $24,000 and upon every annual anniversary thereafter, at the
rate based on the increase in the Consumer Price Index for All Urban Consumers (New York-Northern N.J.-Long Island). Effective
January 1, 2010, this amount was added to Mr. Mahoney’s base salary. On June 15, 2010, Mr. Mahoney’s employment
agreement was amended to increase the base salary to $195,000 effective July 1, 2010. All other terms of the Employment Agreement
shall remain in full force and effect. A portion of Mr. Mahoney’s compensation shall be deferred until such time that the
Board of Directors determines that the Company has sufficient financial resources to pay his compensation in cash. For the three
months ended March 31, 2016, Mr. Mahoney drew $3,000 of his salary and the remainder was accrued to deferred compensation. The
Board has the option to pay Mr. Mahoney’s compensation in the form of Class B Common Stock. Mr. Mahoney will also be entitled
to certain bonuses based on mergers and acquisitions completed by the Company. Pursuant to the terms of the Class B Common Stock,
a holder of Class B Common Stock has the right to convert each share of Class B Common Stock into the number of shares of Class
A Common Stock determined by dividing the number of Class B Common Stock being converted by a 20% discount of the lowest price
for which the Company had ever issued its Class A Common Stock. On August 28, 2014, the Company converted $148,396 of deferred
compensation into 148,396 shares of Class B Common Stock. On September 15, 2014, the Company received a forgiveness of debt in
the amount of $500,000 from Mr. Mahoney. As of March 31, 2016 and December 31, 2015, total deferred compensation and accrued interest
due to Mr. Mahoney was $840,536 and $785,314 respectively.

9. Income Taxes

9. Income Taxes6 Months Ended
Jun. 30, 2016
Income Tax Disclosure [Abstract]
9. Income TaxesThe
tax effect of temporary differences, primarily net operating loss carry forwards, asset reserves and accrued liabilities give
rise to a deferred tax asset. Deferred income taxes are recognized for the tax consequence of such temporary differences at the
enacted tax rate expected to be in effect when the differences reverse. Because of the current uncertainty of realizing the benefit
of the tax carry forward, a valuation allowance equal to the tax benefit for deferred taxes has been established. The full realization
of the tax benefit associated with the carry forward depends predominantly upon the Company's ability to generate taxable income
during the carry forward period.

4. Summary of Significant Acc12

4. Summary of Significant Accounting Policies (Policies)6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]
a) Basis of Presentationa) Basis
of Presentation The accompanying
condensed unaudited interim financial statements included herein have been prepared, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission ("SEC"). The condensed financial statements and notes are presented
as permitted on Form 10-Q and do not contain information included in the Company's annual statements and notes. Certain information
and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company
believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed
financial statements be read in conjunction with the March 31, 2015 financial statements and the accompanying notes thereto. While
management believes the procedures followed in preparing these condensed financial statements are reasonable, the accuracy of
the amounts are in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company
later in the year. These results are not necessarily indicative of the results to be expected for the full year. These condensed
unaudited financial statements reflect all adjustments, including normal recurring adjustments, which, in the opinion of management,
are necessary to present fairly the operations and cash flows for the periods presented.
b) Use of Estimatesb) Use
of Estimates The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.
c) Revenue Recognitionc) Revenue
Recognition In
addition to cash flow generated from sale of natural supplements such as:
· Diabetes
· Lung
cleanse
· Seal
oil
· Prostate
· Stress
less Company intends
to produce the “health phone” that will significantly increase demand in their product and enlarge the product purchase.
Clients will be able to purchase products through this smartphone and it contains application that measure heartbeat, calories,
fat, excises schedule etc. The most important thing is that clients will have this option to talk to health specialists.
d) Product Warrantiesd) Product
Warranties The Company estimates
its warranty costs based on historical warranty claims experience in estimating potential warranty claims. Management has determined
that warranty costs are immaterial and has not included an accrual for potential warranty claims. Presently, costs related to
warranty coverage are expensed as incurred. Warranty claims are reviewed quarterly to verify that warranty liabilities properly
reflect any remaining obligation based on the anticipated expenditures over the balance of the obligation period.
e) Research and Development Costse) Research
and Development Costs Research and
development costs are charged to expense when incurred. The Company has not incurred any research and development costs for the
six months ended June 30, 2016.
f) Advertising Costsf) Advertising
Costs Advertising costs
are expensed as incurred and are included in selling expenses. The Company has incurred advertising costs for the six months ended
June 30, 2016 and it counts $16,008.72 USD.
g) Cash and Cash Equivalentsg) Cash
and Cash Equivalents The Company considers
all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. There were no
cash equivalents at June 30, 2016 and March 31, 2015. The Company maintains cash balances at financial institutions that are insured
by the Federal Deposit Insurance Corporation (“FDIC”) up to federally insured limits. At times balances may exceed
FDIC insured limits. The Company has not experienced any losses in such accounts.
h) Concentration of Credit Riskh) Concentration
of Credit Risk Financial instruments
that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable and cash.
As of June 30, 2016 the Company believes it has no significant risk related to its concentration within its accounts receivable.
j) Accounts Receivablej) Accounts
Receivable Accounts receivable
are non-interest bearing obligations due under normal trade terms. Senior management reviews accounts receivable on a monthly
basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are
used in evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined
to be uncollectible, along with a general reserve, in its overall allowance for doubtful accounts. After all attempts to collect
a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company
believes its allowance for doubtful accounts as of June 30, 2016 and March 31, 2015 is adequate.
j) Property and Equipmentj) Property
and Equipment Property and
equipment is stated at cost. Depreciation is computed using the straight-line method based upon the estimated useful lives of
the assets, generally five to seven years. Maintenance and repairs are charged to expense as incurred.
k) Intangible Assetsk) Intangible
Assets Registration
and maintenance costs associated with the filing and registration of patents are prepaid and amortized over the remaining life
of the patent, not to exceed 20 years. Costs associated with such patents are not approved or abandoned.
l) Income Taxesl) Income
Taxes The Company accounts
for income taxes using the asset and liability method described in FASB ASC 740. Deferred tax assets arise from a variety of sources,
the most significant being: a) tax losses that can be carried forward to be utilized against profits in future years; b) expenses
recognized in the books but disallowed in the tax return until the associated cash flow occurs; and c) valuation changes of assets
which need to be tax effected for book purposes but are deductible only when the valuation change is realized. Deferred tax
assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities
and are measured using enacted tax rates and laws that are expected to be in effect when such differences are expected to reverse. The
measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefit, which is not more likely
than not to be realized. In assessing the need for a valuation allowance, future taxable income is estimated, considering the
realization of tax loss carryforwards. Valuation allowances related to deferred tax assets can also be affected by changes to
tax laws, changes to statutory tax rates and future taxable income levels. In the event it was determined, that the Company would
not be able to realize all or a portion of our deferred tax assets in the future, we would reduce such amounts through a charge
to income in the period in which that determination is made. Conversely, if we were to determine that we would be able to realize
our deferred tax assets in the future in excess of the net carrying amounts, we would decrease the recorded valuation allowance
through an increase to income in the period in which that determination is made. In its evaluation of a valuation allowance, the
Company takes into account existing contracts and backlog, and the probability that options under these contract awards will be
exercised as well as sales of existing products. The Company prepares profit projections based on the revenue and expenses forecast
to determine that such revenues will produce sufficient taxable income to realize the deferred tax assets. The Company adopted
FASB ASC 740-10-50, Accounting for Uncertainty in Income Taxes. ASC 740-10-50 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
ASC 740-10 requires that the Company determine whether the benefits of its tax positions are more-likely-than-not of being sustained
upon audit based on the technical merits of the tax position. The Company recognizes the impact of an uncertain income tax position
taken on its income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing
authority. Despite the Company’s
belief that its tax return positions are consistent with applicable tax laws, one or more positions may be challenged by taxing
authorities. Settlement of any challenge can result in no change, a complete disallowance, or some partial adjustment reached
through negotiations or litigation. Interest and
penalties related to income tax matters, if applicable, will be recognized as income tax expense. During the three months ended
June 30, 2016 and 2015, the Company did not incur any expense related to interest or penalties for income tax matters, and no
such amounts were accrued as of June 30, 2016 and March 31, 2015.
m) Fair Value of Financial Instrumentsm) Fair
Value of Financial Instruments The carrying
amounts reported in the balance sheets as of June 30, 2016 and March 31, 2015 for cash and cash equivalents, marketable securities,
accounts receivable, inventories, prepaid expenses and other current assets, accounts payable and accrued expenses other current
liabilities approximate the fair value because of the immediate or short-term maturity of these financial instruments. The
fair value of the debt approximates its carrying value at the stated discount rate of the debt to reflect recent market conditions.
n) Long-Lived Assetsn) Long-Lived
Assets The Company assesses
the recoverability of the carrying value of its long-lived assets whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of
the carrying amount of an asset to future, undiscounted cash flows expected to be generated by an asset. If such assets
are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets
exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or
fair value less costs to sell. No impairment losses were recognized for the six months ended June 30, 2016 and 2015.
o) Recent Accounting Pronouncementso) Recent
Accounting Pronouncements There were various
other updates recently issued, most of which represented technical corrections to the accounting literature or application to
specific industries and are not expected to a have a material impact on the Company's financial position, results of operations
or cash flows.

4. Summary of Significant Acc13

4. Summary of Significant Accounting Policies (Details Narrative)6 Months Ended
Jun. 30, 2016USD ($)
Accounting Policies [Abstract]
Research and development expenses $ 0
Advertising costs16,009
Cash equivalents $ 0